As of 4:00pm ET
| 0.00 / 0.00%|
The 1 analysts offering 12-month price forecasts for Plus Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The median estimate represents a +336.36% increase from the last price of 2.75.
The current consensus among 1 polled investment analysts is to Buy stock in Plus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.